Gao's position exposure in the third quarter: 22 new companies, 10 biopharmaceutical companies

On November 17th, Beijing time, Gao announced its positions in U.S. stocks at the end of the third quarter of 2020.
data show that Gao holds 89 companies in the U.S. stock market, with biomedicine, Internet and hard technology as the main areas, with a market capitalization of $13.2 billion, up more than 20 percent from $10.94 billion held at the end of the second quarter of this year.
note that 10 of the 22 new companies in the third quarter were in the biopharmaceutical sector.
89 holding companies, 47 are in the life and health sector.
, Gao has invested eight times in a row in Baiji Shenzhou, ranked in the top five heavy positions in several quarters, in the third quarter position data, Baiji Shenzhou's holding market value ranked No. 2.
the end of the third quarter, Gao held a value of $1.567 billion in Baiji Shenzhou City.
public information, Baiji Shenzhou is a major research and development of cancer innovative drugs and cancer immunopharmaceutical development and commercialization of biopharmaceutical companies.
the company was dually listed on NASDAQ and HKEx in 2016 and 2018, respectively, and plans to list on the Board in 2021.
of the 11 independently developed clinical drugs in Baiji Shenzhou has been approved for market.
from the financial data, since its establishment, Baiji Shenzhou has been in a loss-making state.
, however, Gao Gao seemed patient with Baiji Shenzhou.
from the starting period in 2015 to the NASDAQ listing in 2016, to the targeted issue after the listing, to the Hong Kong listing in 19 years, Gao has always been involved in investment.
On July 13 this year, Baiji Shenzhou announced that it would issue 145,838,979 shares of common stock with a face value of $0.0001 per share to certain existing investors in a registered direct offering, and that the shares would be sold at a purchase price of $14.2308 per common share, of which Gao had subscribed for no less than $1 billion.
, Gao's capital has invested in Baiji Shenzhou eight times.
in terms of stock price movements, Baiji Shenzhou is also all the way up, especially the U.S. share price, which has risen eightfold in four years.
Taibang Bio is also ranked among the top ten heavy stocks in the third quarter, is a long-term heavy position holding company.
the end of the third quarter, Gao held a market capitalisation of $329 million.
public information shows that Taibang Bio was officially listed on NASDAQ in 2009, its core business mainly includes plasma collection, blood products and biofilm materials research and development, production and sales, product lines cover albumin, immunoglobulin and clotting factors in three categories of more than 20 different specifications of blood products, and other biopharmaceutical products.
addition, from the third quarter of the increase in holdings and new companies, it can be clearly seen that its investment in digital cells, rare diseases, muscle diseases and other sub-sectors of life and health continued to increase investment.
is learned that Gao has invested more than 200 enterprises in biomedicine, medical devices, medical services, pharmaceutical retailing and other fields, including more than 100 Chinese enterprises, with a total investment of more than 150 billion yuan.
it is worth mentioning that since 2014, when Gaoji Capital invested in Baiji Shenzhou, the agency has carried out a systematic and intensive layout.
In the field of innovative drugs, Gao Yu has invested in Gan Li Pharmaceuticals, Junshi Bio, Xinda Bio, Hengrui Pharmaceuticals, etc., in the field of medical intervention, has invested in Peijia Medical, Qiming Medical, minimally invasimable heart, and deep upstream and downstream investment in intervention imaging companies;
, it can be seen that Gao Gao has started a new wave of investment in the field of biomedicine in China.